ALNYLAM PHARMACEUTICALS, INC. Research and Development Expense
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Research and Development Expense of $413.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $413.13M, a 27.66% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $372.22M, a 24.00% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $358.81M, a 32.44% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-06-30 was $323.62M, a 10.02% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $1.32B, a 17.19% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $1.13B, a 12.13% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $1.00B, a 13.75% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $883.01M, a 11.47% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $413.13M 10-Q · filed 2026-07-30 | $778.00M 10-Q · filed 2026-07-30 | ||
| 2025-12-31 | $372.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $731.03M derived: sum of 2 quarters · filed 2026-02-12 | $1.05B derived: sum of 3 quarters · filed 2026-07-30 | $1.32B 10-K · filed 2026-02-12 |
| 2025-09-30 | $358.81M 10-Q · filed 2025-10-30 | $682.43M derived: sum of 2 quarters · filed 2026-07-30 | $947.56M 10-Q · filed 2025-10-30 | $1.25B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $323.62M 10-Q · filed 2026-07-30 | $588.74M 10-Q · filed 2026-07-30 | $888.91M derived: sum of 3 quarters · filed 2026-07-30 | $1.16B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $265.12M 10-Q · filed 2025-05-01 | $565.29M derived: sum of 2 quarters · filed 2026-02-12 | $836.22M derived: sum of 3 quarters · filed 2026-02-12 | $1.13B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $300.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $571.10M derived: sum of 2 quarters · filed 2026-02-12 | $865.24M derived: sum of 3 quarters · filed 2026-02-12 | $1.13B 10-K · filed 2026-02-12 |
| 2024-09-30 | $270.93M 10-Q · filed 2025-10-30 | $565.07M derived: sum of 2 quarters · filed 2025-10-30 | $826.06M 10-Q · filed 2025-10-30 | $1.10B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $294.14M 10-Q · filed 2025-07-31 | $555.14M 10-Q · filed 2025-07-31 | $827.28M derived: sum of 3 quarters · filed 2026-02-12 | $1.08B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $261.00M 10-Q · filed 2025-05-01 | $533.14M derived: sum of 2 quarters · filed 2026-02-12 | $786.32M derived: sum of 3 quarters · filed 2026-02-12 | $1.03B derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $272.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $525.32M derived: sum of 2 quarters · filed 2026-02-12 | $773.85M derived: sum of 3 quarters · filed 2026-02-12 | $1.00B 10-K · filed 2026-02-12 |
| 2023-09-30 | $253.18M 10-Q · filed 2024-10-31 | $501.70M derived: sum of 2 quarters · filed 2024-10-31 | $732.27M 10-Q · filed 2024-10-31 | $994.31M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $248.53M 10-Q · filed 2024-08-01 | $479.10M 10-Q · filed 2024-08-01 | $741.13M derived: sum of 3 quarters · filed 2025-02-13 | $986.50M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $230.57M 10-Q · filed 2024-05-02 | $492.61M derived: sum of 2 quarters · filed 2025-02-13 | $737.98M derived: sum of 3 quarters · filed 2025-02-13 | $943.69M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $262.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $507.41M derived: sum of 2 quarters · filed 2025-02-13 | $713.12M derived: sum of 3 quarters · filed 2025-02-13 | $883.01M 10-K · filed 2025-02-13 |
| 2022-09-30 | $245.37M 10-Q · filed 2023-11-02 | $451.08M derived: sum of 2 quarters · filed 2023-11-02 | $620.98M 10-Q · filed 2023-11-02 | $850.03M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $205.71M 10-Q · filed 2023-08-03 | $375.61M 10-Q · filed 2023-08-03 | $604.65M derived: sum of 3 quarters · filed 2024-02-15 | $799.23M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $169.89M 10-Q · filed 2023-05-04 | $398.94M derived: sum of 2 quarters · filed 2024-02-15 | $593.51M derived: sum of 3 quarters · filed 2024-02-15 | $776.15M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $229.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $423.62M derived: sum of 2 quarters · filed 2024-02-15 | $606.26M derived: sum of 3 quarters · filed 2024-02-15 | $792.16M 10-K · filed 2024-02-15 |
| 2021-09-30 | $194.57M 10-Q · filed 2022-10-27 | $377.21M derived: sum of 2 quarters · filed 2022-10-27 | $563.11M 10-Q · filed 2022-10-27 | $731.58M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $182.63M 10-Q · filed 2022-07-28 | $368.53M 10-Q · filed 2022-07-28 | $537.00M derived: sum of 3 quarters · filed 2023-02-23 | $698.79M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $185.90M 10-Q · filed 2022-04-28 | $354.37M derived: sum of 2 quarters · filed 2023-02-23 | $516.15M derived: sum of 3 quarters · filed 2023-02-23 | $671.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $168.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $330.25M derived: sum of 2 quarters · filed 2023-02-23 | $485.25M derived: sum of 3 quarters · filed 2023-02-23 | $654.82M 10-K · filed 2023-02-23 |
| 2020-09-30 | $161.78M 10-Q · filed 2021-10-28 | $316.78M derived: sum of 2 quarters · filed 2021-10-28 | $486.35M 10-Q · filed 2021-10-28 | $687.65M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $155.00M 10-Q · filed 2021-08-03 | $324.57M 10-Q · filed 2021-08-03 | $525.87M derived: sum of 3 quarters · filed 2022-02-10 | $686.66M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $169.57M 10-Q · filed 2021-04-29 | $370.87M derived: sum of 2 quarters · filed 2022-02-10 | $531.67M derived: sum of 3 quarters · filed 2022-02-10 | $695.56M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $201.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $362.10M derived: sum of 2 quarters · filed 2022-02-10 | $525.99M derived: sum of 3 quarters · filed 2022-02-10 | $655.11M 10-K · filed 2022-02-10 |
| 2019-09-30 | $160.80M 10-Q · filed 2020-11-05 | $324.69M derived: sum of 2 quarters · filed 2020-11-05 | $453.81M 10-Q · filed 2020-11-05 | $584.85M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $163.89M 10-Q · filed 2020-08-06 | $293.02M 10-Q · filed 2020-08-06 | $424.05M derived: sum of 3 quarters · filed 2021-02-11 | $564.00M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $129.13M 10-Q · filed 2020-05-06 | $260.16M derived: sum of 2 quarters · filed 2021-02-11 | $400.11M derived: sum of 3 quarters · filed 2021-02-11 | $537.69M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $131.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $270.98M derived: sum of 2 quarters · filed 2021-02-11 | $408.56M derived: sum of 3 quarters · filed 2021-02-11 | $505.42M 10-K · filed 2021-02-11 |
| 2018-09-30 | $139.94M 10-Q · filed 2019-10-31 | $277.53M derived: sum of 2 quarters · filed 2019-10-31 | $374.38M 10-Q · filed 2019-10-31 | $492.16M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $137.58M 10-Q · filed 2019-08-06 | $234.44M 10-Q · filed 2019-08-06 | $352.21M derived: sum of 3 quarters · filed 2020-02-13 | $447.46M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $96.86M 10-Q · filed 2019-05-02 | $214.63M derived: sum of 2 quarters · filed 2020-02-13 | $309.88M derived: sum of 3 quarters · filed 2020-02-13 | $400.51M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $117.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $213.02M derived: sum of 2 quarters · filed 2020-02-13 | $303.65M derived: sum of 3 quarters · filed 2020-02-13 | $390.63M 10-K · filed 2020-02-13 |
| 2017-09-30 | $95.25M 10-Q · filed 2018-11-07 | $185.88M derived: sum of 2 quarters · filed 2018-11-07 | $272.86M 10-Q · filed 2018-11-07 | $377.87M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | $90.63M 10-Q · filed 2018-08-02 | $177.61M 10-Q · filed 2018-08-02 | $282.62M derived: sum of 3 quarters · filed 2019-02-14 | $380.56M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $86.98M 10-Q · filed 2018-05-04 | $192.00M derived: sum of 2 quarters · filed 2019-02-14 | $289.93M derived: sum of 3 quarters · filed 2019-02-14 | $373.10M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $105.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $202.95M derived: sum of 2 quarters · filed 2019-02-14 | $286.12M derived: sum of 3 quarters · filed 2019-02-14 | $382.39M 10-K · filed 2019-02-14 |
| 2016-09-30 | $97.94M 10-Q · filed 2017-11-07 | $181.11M derived: sum of 2 quarters · filed 2017-11-07 | $277.38M 10-Q · filed 2017-11-07 | $360.22M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $83.17M 10-Q · filed 2017-08-09 | $179.44M 10-Q · filed 2017-08-09 | $262.28M derived: sum of 3 quarters · filed 2018-02-15 | $330.90M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $96.27M 10-Q · filed 2017-05-05 | $179.11M derived: sum of 2 quarters · filed 2018-02-15 | $247.73M derived: sum of 3 quarters · filed 2018-02-15 | $314.73M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $82.83M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $151.45M derived: sum of 2 quarters · filed 2018-02-15 | $218.46M derived: sum of 3 quarters · filed 2018-02-15 | $276.50M 10-K · filed 2018-02-15 |
| 2015-09-30 | $68.62M 10-Q · filed 2016-11-03 | $135.63M derived: sum of 2 quarters · filed 2016-11-03 | $193.66M 10-Q · filed 2016-11-03 | $249.21M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $67.01M 10-Q · filed 2016-08-04 | $125.04M 10-Q · filed 2016-08-04 | $180.59M derived: sum of 3 quarters · filed 2017-02-15 | $226.86M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $58.03M 10-Q · filed 2016-05-04 | $113.58M derived: sum of 2 quarters · filed 2017-02-15 | $159.85M derived: sum of 3 quarters · filed 2017-02-15 | $204.53M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $55.55M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $101.82M derived: sum of 2 quarters · filed 2017-02-15 | $146.49M derived: sum of 3 quarters · filed 2017-02-15 | $190.25M 10-K · filed 2017-02-15 |
| 2014-09-30 | $46.27M 10-Q · filed 2015-11-09 | $90.94M derived: sum of 2 quarters · filed 2015-11-09 | $134.70M 10-Q · filed 2015-11-09 | $166.81M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $44.67M 10-Q · filed 2015-08-07 | $88.43M 10-Q · filed 2015-08-07 | $120.54M derived: sum of 3 quarters · filed 2016-02-12 | $154.99M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $43.76M 10-Q · filed 2015-05-08 | $75.86M derived: sum of 2 quarters · filed 2016-02-12 | $110.32M derived: sum of 3 quarters · filed 2016-02-12 | $134.54M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $32.11M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $66.56M derived: sum of 2 quarters · filed 2016-02-12 | $90.78M derived: sum of 3 quarters · filed 2016-02-12 | $112.96M 10-K · filed 2016-02-12 |
| 2013-09-30 | $34.46M 10-Q · filed 2014-11-06 | $58.67M derived: sum of 2 quarters · filed 2014-11-06 | $80.85M 10-Q · filed 2014-11-06 | $102.53M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $24.21M 10-Q · filed 2014-08-08 | $46.39M 10-Q · filed 2014-08-08 | $68.07M derived: sum of 3 quarters · filed 2015-02-13 | $90.17M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $22.18M 10-Q · filed 2014-05-09 | $43.86M derived: sum of 2 quarters · filed 2015-02-13 | $65.95M derived: sum of 3 quarters · filed 2015-02-13 | $87.67M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $21.68M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $43.77M derived: sum of 2 quarters · filed 2015-02-13 | $65.50M derived: sum of 3 quarters · filed 2015-02-13 | $86.57M 10-K · filed 2015-02-13 |
| 2012-09-30 | $22.09M 10-Q · filed 2013-11-07 | $43.82M derived: sum of 2 quarters · filed 2013-11-07 | $64.89M 10-Q · filed 2013-11-07 | $88.26M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $21.72M 10-Q · filed 2013-08-09 | $42.80M 10-Q · filed 2013-08-09 | $66.17M derived: sum of 3 quarters · filed 2014-02-20 | $90.44M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $21.07M 10-Q · filed 2013-05-07 | $44.44M derived: sum of 2 quarters · filed 2014-02-20 | $68.72M derived: sum of 3 quarters · filed 2014-02-20 | $94.02M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $23.37M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $47.64M derived: sum of 2 quarters · filed 2014-02-20 | $72.95M derived: sum of 3 quarters · filed 2014-02-20 | $99.30M 10-K · filed 2014-02-20 |
| 2011-09-30 | $24.27M 10-Q · filed 2012-11-05 | $49.58M derived: sum of 2 quarters · filed 2012-11-05 | $75.93M 10-Q · filed 2012-11-05 | $102.01M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $25.30M 10-Q · filed 2012-08-08 | $51.65M 10-Q · filed 2012-08-08 | $77.73M derived: sum of 3 quarters · filed 2013-02-19 | $105.20M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $26.35M 10-Q · filed 2012-05-03 | $52.43M derived: sum of 2 quarters · filed 2013-02-19 | $79.90M derived: sum of 3 quarters · filed 2013-02-19 | $108.03M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $26.08M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $53.55M derived: sum of 2 quarters · filed 2013-02-19 | $81.68M derived: sum of 3 quarters · filed 2013-02-19 | $106.38M 10-K · filed 2013-02-19 |
| 2010-09-30 | $27.47M 10-Q · filed 2011-11-03 | $55.60M derived: sum of 2 quarters · filed 2011-11-03 | $80.30M 10-Q · filed 2011-11-03 | $101.88M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | $28.14M 10-Q · filed 2011-08-03 | $52.84M 10-Q · filed 2011-08-03 | $74.41M derived: sum of 3 quarters · filed 2012-02-13 | $97.63M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | $24.70M 10-Q · filed 2011-05-05 | $46.27M derived: sum of 2 quarters · filed 2012-02-13 | $69.49M derived: sum of 3 quarters · filed 2012-02-13 | $108.11M derived: sum of 4 quarters · filed 2012-02-13 |
| 2009-12-31 | $21.57M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | $44.79M derived: sum of 2 quarters · filed 2012-02-13 | $83.41M derived: sum of 3 quarters · filed 2012-02-13 | $108.73M 10-K · filed 2012-02-13 |
| 2009-09-30 | $23.22M 10-Q · filed 2010-11-04 | $61.83M derived: sum of 2 quarters · filed 2010-11-04 | $87.16M 10-Q · filed 2010-11-04 | |
| 2009-06-30 | $38.62M 10-Q · filed 2010-08-05 | $63.94M 10-Q · filed 2010-08-05 | ||
| 2008-12-31 | $96.88M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |